Around 1.2 million Canadians suffering from knee osteoarthritis (OA) could now benefit from fast, lasting pain relief supplied by the OdrA orthotic device, a new generation of orthotics launched by Ergoresearch.
OdrA (OrthÃ¨se de Distraction et Rotation pour Arthrose) summarises an OA distraction-rotation orthotic device. Developed by Proteor Group, Ergoresearch's partner, the worldwide patented orthotic device is the result of global research, development and marketing. Its mechanism improves knee mobility by decreasing pain-causing intra-articular pressure. According to a recent report by the Arthritis Alliance of Canada, direct and indirect costs associated with osteoarthritis soared to C$27.5 million in the country in 2010, of which US$7.2 million were attributed to knee OA.
Knee OA is characterised by the wear and deformity of cartilage covering the femur and tibia bone extremities, causing pain linked to friction between joint surfaces. Compared with traditional devices, the OdrA mechanism's distraction-rotation combination only functions when appropriate, once the leg is fully extended. By combining a slight external rotation of the foot with a distraction, which is when the space between the tibia and the femur is extended, the mechanism decreases the weight on the medial knee compartment and lightens load bearing, thereby lessening pain and providing the joint with greater mobility.
Ãtude OrfÃ¨vre, a study conducted at the Dijon University Hospital (CHU Dijon, France) in 2010, combined with follow-up among participants who wore the device over a 12-month period have revealed that 85 per cent of patients rated their condition as improved or significantly improved. The results of the study, which was conducted according to international gonarthrosis standards of reference, demonstrate that of all the treatments currently available on the market, with the exception of knee replacement surgery, the OdrA device is the only one that significantly relieves pain. After evaluation and comparison, the orthotic device shows a 1.8 range of effectiveness on a scale where the significant pain relief threshold is 0.8 (low: <0.5; moderate: 0.5 - 0.8; significant: >0.8).